In 2009 the seasonal influenza virus was replaced with a pandemic H1N1 infection strain (swine flu). Since that time, numerous reports have surfaced of severe disease occurring and resulting in acute lung injury and mortality. Treatment of this infection has involved oseltamavir and supportive care. A logical next step would be to find an adjuvant agent that could be of benefit in severe disease. To discover this agent, one must first understand the pathogenesis of this unique virus.

In the previous issue of Critical Care, Schouten and colleagues attempt to build on the knowledge gained about the pathogenesis of H1N1 in a lethal mouse model [1]. These authors ask two questions. Does viral pneumonia due to H1N1 cause systemic and pulmonary activation of coagulation and inhibition of fibrinolysis in the lungs similar to what is known to occur in community-acquired bacterial pneumonia and acute respiratory distress syndrome? If so, does activated protein C (APC) – a molecule with anticoagulant, anti-inflammatory and profibrinolytic properties – abrogate this response and improve outcome, as is suggested by its effects in patients with sepsis due to community-acquired pneumonia [2]?

The results of Schouten and colleagues’ study indicate that activation of coagulation and impairment of fibrinolysis does in fact occur during H1N1 infection. They also corroborate the findings of intense neutrophil influx in the lung, prolonged cytokine storm and diffuse alveolar damage as key components of the pathogenesis of the infection [3]. APC was able to decrease coagulation activation and restore normal fibrinolysis compared with placebo but had marginal effects on cytokine levels, pulmonary neutrophil influx and outcome.

The results from this animal study add to the evidence that coagulation inhibition per se does not improve outcome in acute lung injury. A randomized, placebo-controlled trial of recombinant human APC in 75 patients with acute lung injury without sepsis demonstrated no benefit of APC with respect to ventilator-free days, mortality or lung injury score [4]. A trial of a recombinant tissue factor pathway inhibitor in patients with severe community-acquired pneumonia demonstrated no benefit (Wunderiak R, et al., unpublished data).

A possible downside to thrombin inhibition by anticoagulation agents is the loss of the ability to wall off infection through fibrin formation. Fortunately, APC led to lower viral load in the lungs. Additionally, inhibition of thrombin formation could prevent the activation of thrombin activatable fibrinolysis inhibitor. Activated thrombin activatable fibrinolysis inhibitor inhibits the chemotactic factors C3a and C5a, which could be important for prevention of influx of leukocytes into the lung [5]. As the authors of the current study mention, mutant variants of APC with anti-inflammatory properties and little anticoagulant activity could be examined in future animal studies.

The lack of effect of APC on cytokine production and neutrophil influx that is prominent in H1N1 merits discussion. The current study’s authors showed that APC had no effect on cytokine elaboration or pulmonary
neutrophil influx in a \textit{Pseudomonas aeruginosa} pneumonia model and in an endotoxin challenge model in rats [6,7]. \textit{In vitro} models have demonstrated an inhibitory effect of APC on cytokine effect with much higher concentrations of APC relative to the levels achieved in this study [8]. In both a human and a sheep pulmonary endotoxin study, recombinant human APC given as a continuous infusion of 24 \(\mu\)g/kg/hour was able to decrease the infiltration of neutrophils into the lung [9,10]. In human septic patients and in an intravenous endotoxin challenge model in healthy human volunteers, no anti-inflammatory effects were observed with this dosing strategy [11,12]. These data would suggest that the anti-inflammatory effects of APC vary by species, by type of infectious challenge, by means of APC dosing and by blood concentrations, such that more information needs to be learned with respect to optimized dosing in H1N1 infection. Future animal studies with the previously mentioned APC variants with minimal anticoagulant effects would allow the authors to push the blood concentration for determination of the maximal anti-inflammatory effect.

The absence of a benefit in terms of survival with APC treatment in this murine model of H1N1 infection does not necessarily predict a lack of benefit in human H1N1 infection. This model was quite severe with 100% lethality, while mortality in human H1N1 infection is less than 20% in severe cases [13,14]. The mice were young, healthy and of normal weight, which does not mimic the clinical situation in humans. Oseltamivir was not given in this model, which could affect the treatment response to APC. Upwards of 30% of human patients with H1N1 develop bacterial pneumonia and severe sepsis in which recombinant human APC may still be beneficial [3]. Severe human H1N1 infection is complicated by shock in 30 to 60% of cases and by renal failure in 22% of cases [13,14]. This animal model did not monitor organ dysfunction, which APC may prevent through PAR-1 signaling [15].

In summary, the jury is still out regarding whether APC could potentially play a future role in the management of H1N1 infection. Future experiments will need to include mice and other species of different ages, different infecting doses of H1N1, concomitant oseltamivir treatment, monitoring and evaluation of hemodynamic and non-pulmonary organ function, and different dosages and means of administration of APC and APC variants.

\textbf{Abbreviations}

APC, activated protein C.

\textbf{Competing interests}

SPL is a former employee of Eli Lilly and company, the maker of recombinant human activated Protein C.

Published: 18 May 2010

\textbf{References}


